Janus Kinases (JAKs) Inhibitor Drugs Market Dynamics ,Segmentation ,Opportunities

March 28, 2023 | Author: samidha28jain | Category:
Share Embed Donate

Short Description

Download Janus Kinases (JAKs) Inhibitor Drugs Market Dynamics ,Segmentation ,Opportunities...


Janus kinase (JAKs) inhibitors prevent the aberrant action of JAK family enzymes, including JAK1, JAK2, JAK3, and TYK2. These enzymes' suppression contributes to the JAK-STAT signaling pathway, which is essential for the emergence of several autoimmune diseases and cancer indicators. JAK inhibitors are part of the medications known as DMARDs (disease-modifying antirheumatic drugs). The FDA has approved the use of three JAK inhibitors, baricitinib (Olumiant), tofacitinib (Xeljanz), and upadacitinib (Rinvoq), to treat rheumatoid arthritis.
View more...


Copyright � 2017 NANOPDF Inc.